Australia's most trusted
source of pharma news
Wednesday, 16 October 2024
Posted 14 October 2024 AM
Expanding beyond weight loss will see incretins become the highest earning class of pharmaceutical drugs ever, according to a recent report from Evaluate.
According to the report, Obesity: The next questions, many analysts expect the incretin class of drugs to become biopharma's first drug class to hit annual sales of US$100 billion, with some predicting the market could end up closer to US$200 billion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.